Clinical Trial Finder

Inclusion Criteria:

• - Age (18-88 years) - English speaker (written and spoken) - Temporal Mandibular Disorder (TMD) for at least 3 months.

• - TMD Grade Chronic Pain Scale (GCPS) ≥ 0.

Exclusion Criteria:

• - Present or past degenerative neuromuscular disease.

• - Cardiovascular, neurological diseases, pulmonary abnormalities, kidney disease, liver disease, history of cancer within past 3 years.

• - Cervical pain (e.g. stenosis, radiculopathy) - Any personal (or family first degree) history of mania, schizophrenia, or other psychoses.

• - Severe psychiatric condition (e.g. schizophrenia, bipolar disorders, autism) leading to hospitalization within the last 3 years.

• - Use of Antipsychotics (e.g., Risperdal, Ability and clozaril)Lifetime alcohol/drug dependence or alcohol/drug abuse in past 3 months.

• - Pregnancy or breast feeding.

• - Color-blindness.

• - Impaired or uncorrected hearing.

• - Non-dominant hand.

• - Any facial trauma that has occurred in the last 6 weeks.

• - History of a severe facial trauma in the last 2-3 months.

• - Conditions that would interfere with the VR mask placement (e.g. trauma, burn, infection) - Known history of severe motion sickness.

• - Non-removable head cover, artificial hair, certain types of braids or dreadlocks.

• - History of fainting.

• - History of angioedema.

- Failed drug test (testing for opiates, cocaine, methamphetamines, and amphetamines)

Virtual reality (VR) has been seen as an intervention for alleviating clinical chronic (and acute) pain. An approach to pain management utilizing VR presents opportunities for reducing pain and suffering by using immersive, aesthetic, and multisensory stimulation. Investigator will analyze the behavioral and neural mechanisms of active VR against sham VR as two methods that investigate descending pain modulation. Thus, the central hypothesis is that those who respond to placebos will likely respond to active VR. If VR-induced analgesia depends upon the release of endogenous opioids. In this project, the investigators will determine the effects of VR at the neural and clinical levels directly for TMD participants, inviting participants from an existing Colloca Lab-based cohort phenotyped for diagnosis, grade, and low/high impact pain profiles and prospective TMD participants in collaboration with Johns Hopkins University. These participants have agreed to be recontacted for further research. In this study, based on our PAF study and modulation of autonomic measurements via VR, we will determine the role of acute and 3-week VR intervention to help restore PAF oscillations to normal. PAF and autonomic measurements will be collected in TMD participants characterized by low/high-impact pain. All participants will go through Active VR, Sham VR and NH phases (3-week each) where participants will be monitored for changes in cortical excitability via PAF oscillations and clinical benefit via EMA.

Arms

Other: High impact TMD

Other: TMD Phenotype TMD participants will be clinically phenotyped into two between-subject groups based on their score on the Graded Chronic Pain Scale (GCPS). This group will have a GCPS grade 2b, 3, and 4.

Other: Low impact TMD

Other: TMD Phenotype TMD participants will be clinically phenotyped into two between-subject groups based on their score on the Graded Chronic Pain Scale (GCPS). This group will have a GCPS grade 0, 1, and 2a

Interventions

Device: - RelieVRx

Participants will use RelieVRx daily for 20min/day for 3 weeks

Device: - Sham-VR

Participants will use Sham-VR, consisting of video, images, and sound in a head-mounted display but lack the "sense of presence" and immersive features of Active-VR (for example, scene changes with head movement). Participants will use the Sham-VR daily for 20min/day for 3 weeks

Other: - No-VR (natural history control)

Participants will continue regular/usual care without any VR devices (goggles or audiovisual input)